BIONTECH SE SPON. ADRS 1
Commented by Carsten Mainitz on October 9th, 2026 | 09:05 CEST
Weight-Loss Drugs 2.0: Can BioNxt and Merck Catch Up with Novo Nordisk and Eli Lilly? What About BioNTech?
The boom in weight-loss drugs is creating a billion-dollar market within the pharmaceutical industry, with an annual volume of USD 100 billion. Novo Nordisk and Eli Lilly are battling for dominance, while Merck is also entering the fray, albeit still in the early stages. BioNxt Solutions aims to deliver established active ingredients via a dissolvable film, targeting enormous potential with a comparatively low-risk approach. For BioNTech, a substantial cash reserve will determine how much time the company has to deliver its next growth spurt. Where does the greatest stock-market opportunity lie?
Read
Commented by Fabian Lorenz on October 2nd, 2026 | 06:55 CEST
BioNTech: A Setback or a Breakthrough? Micron and Volatus Aerospace Impress with Positive News Flow!
Contrarian investors, take note! An exciting opportunity may currently be emerging at Volatus Aerospace. Drone stocks continue to struggle on the stock market. However, the industry's long-term outlook remains positive in both the military and civilian sectors. While Volatus shares are consolidating, positive news continues to flow with new orders and technological advances. Micron Technology has also delivered strong news. Its record figures for 2026 exceeded estimates. The outlook is also positive. Can this dispel investors' skepticism regarding the sustainability of growth and margins? A sign of weakness or a bold move? This question arises with BioNTech in light of the permanent closure of three sites. The media response has been largely critical. However, there are also positive comments.
Read
Commented by Fabian Lorenz on September 21st, 2026 | 07:45 CEST
Following Stock-Market Legend André Kostolany: Are Siemens Energy, BioNTech or HPQ Silicon Contrarian Plays?
Contrarian investors, take note! The stock market does not always behave rationally. Stock-market legend André Kostolany liked to compare the relationship between a company's performance and its share price to a man out for a walk with his dog. Sometimes the dog runs ahead, sometimes it lags behind, but ultimately both move in the same direction. HPQ Silicon appears to be a case in point. While the company has been releasing one positive announcement after another, its stock has come under pressure. This discrepancy is precisely what makes the stock interesting for contrarian investors. Siemens Energy presents almost the opposite picture. The stock has already priced in a great deal of growth, while analysts are recommending a "Sell". And what about BioNTech?
Read
Commented by Matthias Schomber on September 17th, 2026 | 07:20 CEST
Jungheinrich, BioNTech and Almonty Industries: The Hidden Comeback Opportunities for Your Portfolio
The market environment is currently rather weak, characterized by slightly falling share prices across the stock markets. In the commodities markets, however, especially in oil, prices are rising slightly to more sharply, by contrast. Investors are getting increasingly nervous, a trend also reflected in bond yields. Yet it is precisely in such phases, when nervousness takes over and many market participants throw in the towel, that attractive entry opportunities can emerge for savvy investors. That is why today we are looking at three very different companies that nevertheless have one thing in common: they could be heading for a rebound or an upward move. With BioNTech, we look at a company focused on the oncology sector. Jungheinrich takes us into the world of warehouse logistics and mechanical engineering — a genuine industry veteran. Finally, we turn to Almonty. The company was once a hidden gem in the commodities sector. That is no longer the case, however: given its strategic importance to the Western defence industry, it has become increasingly difficult to overlook. Join us on an analytical journey through financial statements and charts to discover where interesting opportunities may arise in terms of risk and return.
Read
Commented by Jens Castner on September 16th, 2026 | 06:50 CEST
Tungsten, Beer and Vaccines: What Almonty Industries, Heineken and BioNTech Have in Common
A commodities company whose share price has tripled in a single year because an unassuming heavy metal has become a sought-after, scarce commodity. A brewing giant that has been operating a cash cow in Africa for decades and has a clear strategy for increasing margins. A pharmaceutical pioneer writing its next chapter after the end of the COVID boom—with a factory that literally consists of shipping containers. At first glance, Almonty Industries, Heineken and BioNTech do not have much in common. But upon closer inspection, all three are betting on the same underrated market. Here is how you, as an investor, can benefit.
Read
Commented by Carsten Mainitz on September 15th, 2026 | 10:30 CEST
New Approaches to Fighting Cancer: Why Vidac Pharma, BioNTech and Evotec Deserve Attention
Cancer cells use sophisticated defence mechanisms to evade the immune system and reprogram their own metabolism. These mechanisms are now increasingly being targeted by biotech companies. BioNTech has more than EUR 16 billion in cash and is driving the next generation of immunotherapies. Evotec is scaling up drug development through strong alliances but has eroded investor confidence. This skepticism is weighing on its share price. Developments at Vidac Pharma are particularly exciting. The company focuses on the metabolic reprogramming of malignant cells. Results from a potentially groundbreaking Phase 2b trial are imminent. Which approach offers the greatest promise?
Read
Commented by André Will-Laudien on September 8th, 2026 | 09:40 CEST
Biotech: Time to Bet on the Rebound! Evotec and BioNxt in the Takeover Spotlight, Bayer and BioNTech Flush with Cash
After a long dry spell, the biotech sector is on the cusp of a spectacular turnaround, offering bold investors the potential for significant returns. Many innovative biotech stocks are trading well below their all-time highs, yet almost unnoticed, the next major rally is already taking shape behind the scenes. The huge cash reserves of industry giants Bayer and BioNTech are currently fueling takeover speculation across the sector. This colossal capital, running into the billions, is desperately seeking new growth drivers, suddenly putting smaller players on the radar of potential acquirers. At the very top of the hunters' watchlist are the hard-hit Evotec and the disruptive newcomer BioNxt. Both companies boast top-class technology platforms, which, at current levels, almost seem like an exclusive clearance sale. Investors who keep their eyes open and position themselves strategically for the major rebound could get ahead of the looming wave of consolidation. The conditions for an explosive catch-up rally have rarely been this favorable.
Read
Commented by Fabian Lorenz on August 31st, 2026 | 06:45 CEST
Shock at BioNTech! Insider Buying at Nordex! Comeback Story for dynaCERT!
Could dynaCERT become the comeback story of the year? Analysts at GBC Research certainly believe the cleantech stock could rise to EUR 0.48. The shares are currently trading at EUR 0.06. The company's German management team is working hard to engineer a comeback. In particular, it has recently celebrated successes in commercializing its technology in Vietnam and Mexico. Further positive news should follow in the coming months. BioNTech, on the other hand, shocked its shareholders with Friday's announcement. The Phase 2 trial of its cancer immunotherapy candidate for colorectal cancer has been halted. Does this mean the mRNA race against Moderna is lost? The Nordex share has also recently lost momentum. The stock has been moving sideways since February. But now an insider purchase is attracting attention. Not all analysts, however, share the optimism.
Read
Commented by Matthias Schomber on August 24th, 2026 | 08:20 CEST
Cancer Breakthrough and Defense Boom: BioNTech and Moderna Take Off! Can Volatus Aerospace Follow Suit?
In the capital markets, two entirely different future-oriented industries are simultaneously stepping into the spotlight. While in the biotech sector, hopes for groundbreaking cancer therapies are fueling a massive comeback for companies such as Moderna and BioNTech, a highly exciting turnaround candidate may be emerging in the specialized field of unmanned aviation. Investors are rightly asking themselves whether the recent optimism surrounding biotech stocks is underpinned by fundamental strength or whether it is merely a short-lived flash in the pan followed by a sell-off. Those who can now read the right signals in financial data and chart patterns may be able to identify which stocks are poised for the next major trend movements. We take a closer look for you.
Read
Commented by Fabian Lorenz on August 24th, 2026 | 07:35 CEST
Share Price Surges and Buy Ratings: New Price Target for Almonty as CTS EVENTIM and BioNTech Stage Comebacks
What a comeback! Almonty's share price surged by more than 50% in August! There are good reasons for the rally. Tungsten is in short supply in the West and is urgently needed due to the ramp-up in weapons production in the US. In addition, Almonty has released convincing quarterly results and announced a share buyback program. Analysts have recently nearly doubled their price target. BioNTech's share price jump of over 25% is less attributable to the biotech company itself; the stock has benefited from the breakthrough achieved by rival Moderna. Meanwhile, long-term performer CTS EVENTIM also made a comeback last week. Does this mean the stock is returning to its long-term uptrend? Analysts recommend the share as a "Buy".
Read